Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
Price:
2.03
USD
2.53%
Market Closed
Market Cap:
$6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
US |
|
K
|
Kayseri Seker Fabrikasi AS
IST:KAYSE.E
|
TR |
|
Wentworth Resources PLC
F:1W0
|
JE |
|
Capitaland Investment Ltd
OTC:CLILF
|
SG |
|
RioCan Real Estate Investment Trust
TSX:REI.UN
|
CA |
|
Minesto AB
F:7MN
|
SE |
|
ARCA Biopharma Inc
NASDAQ:ABIO
|
US |
|
Almirall SA
F:E2Z
|
ES |
|
Trimegah Sekuritas Indonesia Tbk PT
IDX:TRIM
|
ID |
|
DRA Global Ltd
ASX:DRA
|
AU |
|
eFFECTOR Therapeutics Inc
OTC:EFTR
|
US |
|
M
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
CH |
|
Wuxi Shangji Automation Co Ltd
SSE:603185
|
CN |
|
Green Cross Health Ltd
NZX:GXH
|
NZ |
|
P
|
Premier Synthetics Ltd
BSE:509835
|
IN |
|
T
|
Tianjin Lisheng Pharmaceutical Co Ltd
SZSE:002393
|
CN |
|
B
|
Budimex SA
WSE:BDX
|
PL |
|
Metcash Ltd
ASX:MTS
|
AU |
Income Statement
Earnings Waterfall
Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings Inc
Income Statement
Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings Inc
Currency: USD
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
5
|
6
|
7
|
7
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+71%
|
0
+82%
|
0
+25%
|
0
-9%
|
0
-2%
|
0
-43%
|
0
-2%
|
0
-19%
|
0
-6%
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(1)
|
(1)
|
(1)
|
(2)
|
(5)
|
(6)
|
(8)
|
(8)
|
(7)
|
(10)
|
(8)
|
(8)
|
(8)
|
(6)
|
(6)
|
(7)
|
(6)
|
|
| Selling, General & Administrative |
(1)
|
(1)
|
(1)
|
(2)
|
(4)
|
(6)
|
(8)
|
(8)
|
(7)
|
(10)
|
(8)
|
(8)
|
(8)
|
(6)
|
(6)
|
(6)
|
(6)
|
|
| Research & Development |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
|
| Depreciation & Amortization |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Operating Income |
(1)
N/A
|
(1)
-15%
|
(1)
-96%
|
(2)
-69%
|
(5)
-94%
|
(6)
-33%
|
(8)
-28%
|
(8)
-4%
|
(7)
+10%
|
(10)
-31%
|
(8)
+11%
|
(8)
+0%
|
(8)
+0%
|
(6)
+30%
|
(6)
-7%
|
(7)
-5%
|
(6)
+1%
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
1
|
(0)
|
(1)
|
(1)
|
(2)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Non-Reccuring Items |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(1)
N/A
|
(1)
-24%
|
(2)
-96%
|
(2)
-64%
|
(5)
-89%
|
(5)
-16%
|
(9)
-59%
|
(9)
-9%
|
(8)
+11%
|
(12)
-37%
|
(9)
+24%
|
(8)
+6%
|
(8)
-2%
|
(6)
+30%
|
(6)
-7%
|
(7)
-5%
|
(6)
+1%
|
|
| Net Income | ||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(1)
|
(1)
|
(2)
|
(2)
|
(5)
|
(5)
|
(9)
|
(9)
|
(8)
|
(12)
|
(9)
|
(8)
|
(8)
|
(6)
|
(6)
|
(7)
|
(6)
|
|
| Net Income (Common) |
(1)
N/A
|
(1)
-24%
|
(2)
-96%
|
(2)
-64%
|
(5)
-89%
|
(5)
-16%
|
(9)
-59%
|
(9)
-9%
|
(8)
+11%
|
(12)
-37%
|
(9)
+24%
|
(8)
+6%
|
(8)
-2%
|
(6)
+30%
|
(6)
-7%
|
(7)
-5%
|
(6)
+1%
|
|
| EPS (Diluted) |
-1.95
N/A
|
-2.42
-24%
|
-4.76
-97%
|
-7.78
-63%
|
-14.69
-89%
|
-16.96
-15%
|
-25.13
-48%
|
-23.59
+6%
|
-19.81
+16%
|
-16.37
+17%
|
-11.63
+29%
|
-10.12
+13%
|
-9.35
+8%
|
-3.47
+63%
|
-3.59
-3%
|
-3.72
-4%
|
-3.71
+0%
|
|
Switch to:
Switch to:
See Also
Discover More
